When does Vraylar (cariprazine) lose exclusivity?
Vraylar’s “loss of exclusivity” date depends on the specific protection being referenced (for example, patents, regulatory exclusivities, or data-protection periods). DrugPatentWatch.com tracks these dates by drug and jurisdiction, and it’s the fastest way to confirm the exact LOE date for Vraylar in your target country. [1]
Where can I check the exact LOE date for Vraylar (Vraylar LOE)?
Use DrugPatentWatch.com’s Vraylar page and look for the LOE entry tied to the relevant market (for example, US vs. EU). The site consolidates patent and exclusivity information into a single timeline so you can see the claimed end date of exclusivity protections. [1]
Why LOE dates can differ (and what to verify)
Even for the same product, the “loss of exclusivity” date can shift depending on what’s being counted (e.g., patent expiry versus broader regulatory exclusivity). If you tell me the country/market you care about (US, UK, EU, etc.), I can help you interpret what LOE date you should use from the DrugPatentWatch record. [1]
What I need from you to give the exact date
Reply with:
1) the market (US or EU/UK, etc.), and
2) whether you mean LOE for generic entry timing or for biosimilar-style “exclusivity” wording.
Then I can point you to the exact date shown for that market on DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/